Forgent Power Solutions Target Raised to $60 by Oppenheimer

Oppenheimer raises Forgent Power Solutions price target to $60 on strong quarterly results. Stock up 24%.

Today / 11:02|Last updated: Today / 11:05

Forgent Power Solutions Target Raised to $60 by Oppenheimer — Photo: Prepared by Bond.az

Oppenheimer raised its price target on Forgent Power Solutions (NYSE:FPS) to $60 from $43, maintaining an Outperform rating.

The company's fiscal Q3 2026 results beat consensus estimates for revenue and earnings. Q4 guidance also exceeded expectations. The stock surged 24% in the past week to $50.19.

Oppenheimer highlighted competitive strengths in customization, capacity, agility, and cross-selling, driving growth. New business wins leverage design and manufacturing advantages.

Analysts forecast 73% revenue growth in fiscal 2026, though the stock may be overvalued based on Fair Value analysis.

More News

Prestige Brands Price Target Cut to $72 by Canaccord

Today / 11:43

444

Prestige Brands Price Target Cut to $72 by Canaccord

Canaccord cuts Prestige Brands price target to $72 after sales miss. Despite challenges, the company eyes growth through acquisitions.

ANALYST RATINGS →

Today / 11:32

466

Canaccord Reaffirms GH Research Stock Rating on Phase 3 Progress

Canaccord Genuity keeps Buy rating on GH Research stock as Phase 3 program for GH001 advances. Key financial highlights included.

ANALYST RATINGS →

Today / 11:30

643

Biogen Stock: Alzheimer Drug Shows Promise

Biogen's Alzheimer drug diranersen shows positive Phase 2 results. Stock analysis and future outlook from Bond.az.

ANALYST RATINGS →

Needham cuts Globant target to $50 on lower multiples

Today / 11:23

994

Needham cuts Globant target to $50 on lower multiples

Needham cuts Globant price target to $50 on lower multiples. Bond.az provides detailed analysis and insights.

ANALYST RATINGS →

BTIG Reiterates Neutral on Insight Molecular Amid FDA Review

Today / 11:20

426

BTIG Reiterates Neutral on Insight Molecular Amid FDA Review

BTIG reiterates Neutral rating on Insight Molecular Diagnostics (IMDX) as FDA reviews GraftAssureDx transplant test. Stock up 28% in a week. Revenue surges 116%.

ANALYST RATINGS →

Today / 11:03

891

BTIG Reiterates Boot Barn Buy Rating

BTIG maintains Boot Barn Buy rating and $235 target after Q4 beat. Strong revenue growth and margin performance.

ANALYST RATINGS →

Wolfe Research Boosts AMAT Target to $550

Today / 10:42

838

Wolfe Research Boosts AMAT Target to $550

Wolfe Research raised Applied Materials price target to $550 from $500, citing strong guidance and revenue growth. Shares have gained 154% in the past year.

ANALYST RATINGS →

Today / 10:03

707

Citizens Reiterates Uber Stock Rating on EBITDA

Citizens reiterates Market Outperform rating on Uber with $100 target, citing EBITDA growth and autonomous vehicle potential.

ANALYST RATINGS →

Jefferies Raises AMAT Target to $510 on AI

Today / 10:02

797

Jefferies Raises AMAT Target to $510 on AI

Jefferies raises Applied Materials price target to $510, citing AI growth and strong semiconductor outlook.

ANALYST RATINGS →

Today / 10:01

662

Citizens Reiterates Charles Schwab Stock Rating

Citizens maintains Market Outperform rating on Charles Schwab with $120 price target after investor day. AI viewed as net positive.

ANALYST RATINGS →

BofA hikes Applied Materials target to $540

Today / 10:00

634

BofA hikes Applied Materials target to $540

BofA raises Applied Materials price target to $540 from $465, citing strong outlook and record quarterly results.

ANALYST RATINGS →

Goldman Sachs cuts Regenxbio target to $10

Today / 09:54

881

Goldman Sachs cuts Regenxbio target to $10

Goldman Sachs cuts Regenxbio (NASDAQ:RGNX) price target to $10 from $12 on RGX-202 regulatory uncertainty. Stock down 41% to $6.25.

ANALYST RATINGS →

...